Healius (ASX:HLS) Other Long Term Assets: A$106 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:HLS Healius Ltd ASX:HLS
44 GF Score
Price A$0.35
GF Value A$1.02
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Healius Other Long Term Assets?

Healius ASX:HLS 44 Other Long Term Assets is A$106 Mil as of Dec. 2025. GuruFocus rates ASX:HLS with a GF Score™ of 44/100 and a GF Value™ of A$1.02 (Possible Value Trap). The stock has 7 warning signs investors should review.

Healius's other long-term assets for the quarter that ended in Dec. 2025 was A$106 Mil.

Healius's quarterly other long-term assets increased from Dec. 2024 (A$78 Mil) to Jun. 2025 (A$100 Mil) and increased from Jun. 2025 (A$100 Mil) to Dec. 2025 (A$106 Mil).

Healius's annual other long-term assets increased from Jun. 2023 (A$88 Mil) to Jun. 2024 (A$89 Mil) and increased from Jun. 2024 (A$89 Mil) to Jun. 2025 (A$100 Mil).

Healius Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Healius's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Healius Other Long Term Assets Chart

Healius Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 82.20 68.80 87.90 89.10 100.00

Healius Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.70 89.10 78.10 100.00 106.20
ASX:HLS
44GF Score
Healius Ltd ASX:HLS
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Healius Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of A$106 Mil mean?
Healius (ASX:HLS) has a Other Long Term Assets of A$106 Mil as of Dec. 2025. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Healius and its competitors.
Is Healius' Other Long Term Assets too high?
Healius' current Other Long Term Assets is A$106 Mil. Overall, Healius has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Healius' Other Long Term Assets compare to TMO and DHR?
Healius' Other Long Term Assets of A$106 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Medical Diagnostics & Research company?
A good Other Long Term Assets depends on the Medical Diagnostics & Research industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Healius and its competitors. Healius's current Other Long Term Assets is A$106 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healius stock overvalued right now?
Based on GuruFocus' analysis, Healius (ASX:HLS) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.02, compared to a current price of A$0.35 — trading 65.7% below its estimated fair value. The current Other Long Term Assets is A$106 Mil. Healius' overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Healius (ASX:HLS), the current Other Long Term Assets is A$106 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healius (ASX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, Healius stock appears to be undervalued. The current stock price of A$0.35 is trading 65.7% below its estimated GF Value™ of A$1.02. GuruFocus considers Healius to be Possible Value Trap.

Key valuation signals for ASX:HLS:

  • Other Long Term Assets: A$106 Mil
  • GF Value™: A$1.02 vs. price of A$0.35 (65.7% below fair value)
  • GF Score™: 44/100 with 7 warning signs

No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Healius Business Description

Other Exchanges PGZ:Germany
Address 161 Castlereagh Street, Level 22, Sydney, NSW, AUS, 2000
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
44GF Score

Get the complete analysis for ASX:HLS

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.35
Price
A$1.02
GF Value